Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UCB-J · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Healthy subjects [11C]-UCB-J | EXPERIMENTAL | Net dose of approximately 370 megabecquerel (MBq) of \[11C\]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28 |
| AD patients [11C]-UCB-J | EXPERIMENTAL | Net dose of approximately 370 megabecquerel (MBq) of \[11C\]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28 |
| Name | Type | Description |
|---|---|---|
| [11C]-UCB-J | OTHER | IV radioligand given prior to and during positron emission tomography (PET) scan |
Inclusion Criteria: Group 1 * Healthy male or female age 55 - 75 years old, inclusive, at the time of informed consent. * Mini-mental state examination (MMSE) greater than or equal to 27. Group 2 * Adult males or females age 55 - 75 years old, inclusive, at the time of informed consent. * Confir...
UCB-J is an investigational radioligand being studied for imaging synaptic density. It is currently in Phase 1 clinical development. The drug is being developed by Alkermes plc (ticker: ALKS).
UCB-J is being studied for use in imaging synaptic density in the brain. It is intended for use in healthy individuals and those with Alzheimer's disease, as part of a non-therapeutic feasibility study.
UCB-J is being developed by Alkermes plc, a biopharmaceutical company. Alkermes trades on the stock exchange under the ticker symbol ALKS.
UCB-J is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in an early Phase 1 trial.
UCB-J has one completed clinical trial, NCT03577262, titled 'A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density'. This trial enrolled 19 participants and was conducted in the Netherlands.
Yes, UCB-J is also known as [11C]-UCB-J. The clinical trial NCT03577262 uses the name [11C]-UCB-J to refer to the radioligand being studied for imaging synaptic density.